Phase 4 N=313 Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Asthma
Primary: Asthma Control — 312; 72; 0; 229 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=51 An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
Allergic Rhinitis · Asthma
Primary: The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment. — 25.3; 26.7; -10.3; 0.4 units on a scale — p=0.001
Phase 4 N=188 Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Rhinitis, Allergic, Seasonal · Asthma
Primary: Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS) — 6.5; 5.9; -0.9; -1.4 Score on a scale — p=0.101
Phase 4 N=725 Study Of Allergic Rhinitis In Patients Who Also Have Asthma
Asthma
Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001
N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Phase 3 N=1,992 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Phase 4 N=388 Study of Asthma and Nasal Steroids
Asthma · Rhinitis · Sinusitis
Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale
Phase 4 N=191 Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
Asthma · Allergic Rhinitis
Primary: Change From Baseline for Daytime Asthma Symptom Score — 0.32; 0.16; 0.29; 0.13 Units on scale — p=0.015
Phase 3 N=1,365 Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
Phase 3 N=1,079 Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale
Phase 3 N=333 Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks — -3.9850; -1.9081 score on a scale — p=<0.0001
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
Phase 4 N=150 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid
Seasonal Allergic Rhinitis
Primary: Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline — 4.28; 4.15 Units on a scale
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 3 N=128 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
Allergic Asthma
Primary: Daily Symptom Load — 1.25; 1.10; 1.32; 0.97 units on a scale
Phase 3 N=907 Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.26; -0.48; -0.52; -0.58 Units on a Scale
Phase 3 N=365 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
Rhinitis, Allergic, Perennial · Allergic Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Total Nasal Symptom Score (rTNSS) — -4.226; -2.728 Points on a scale — p=<0.0001
Phase 2 N=606 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS — -3.57; -2.31; -2.96; -1.48 score on a scale
Phase 4 N=60 A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05
Phase 3 N=1,214 Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale
Phase 3 N=716 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Allergic Rhinitis
Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001
Phase 3 N=327 Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
Perennial Allergic Rhinitis
Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…
Phase 3 N=351 A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
Perennial Allergic Rhinitis
Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001
Phase 3 N=829 A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.32; -0.38; -0.47 Units on a Scale
Phase 3 N=547 Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial
Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…
Phase 3 N=704 Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
Rhinitis, Allergic
Primary: Change From Baseline in Total Nasal Symptom Score (Assessed by Participant) — 7.9; 7.8; 7.9; 8.0 Score on a scale — p=0.36
Phase 4 N=64 Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
Allergic Rhinitis
Primary: Total Nasal Congestion Symptom Score — 94; 70; 75; 68 units on a scale
Phase 4 N=140 Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
Rhinitis, Allergic, Perennial and/or Seasonal
Primary: Ratio of Serum Cortisol Area Under Curve [AUC(0-24 hr)] at the End of Treatment to Baseline — 0.938; 0.898 Ratio
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts